Expression and characterisation of recombinant human collagen (COMA)

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

9760.1;3 PFLS-LS

Titre du projet

Expression and characterisation of recombinant human collagen (COMA)

Titre du projet anglais

Expression and characterisation of recombinant human collagen (COMA)

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte	-	-	-
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Anglais)	Expression and characterisation of recombinant human collagen (COMA)
Résumé des résultats (Abstract) (Anglais)	In ubiquitous use, collagens are extracted and purified from natural sources. The non-uniformity of such raw materials, being composed of several different collagen types, and safety concerns hamper their use for biomaterials or pharmaceuticals. To overcome these obstacles, recombinant technology will be trialled. Samples of rh-procollagen (with intact triple helix structure) to be used for prototyping new medical materials (e.g. synthetic tissues) will be gained from high-cell-density processes with a yeast expression system. Moreover, the experimental data collected will provide first estimates of manufacturing costs in terms of (i) raw materials and (ii) capability figures for the cultivation, downstream and further biosynthetic processing needed to achieve the mature functional form required.

Catégorie

Texte

Description succincte
(Anglais)

Expression and characterisation of recombinant human collagen (COMA)

Résumé des résultats (Abstract)
(Anglais)

In ubiquitous use, collagens are extracted and purified from natural sources. The non-uniformity of such raw materials, being composed of several different collagen types, and safety concerns hamper their use for biomaterials or pharmaceuticals. To overcome these obstacles, recombinant technology will be trialled. Samples of rh-procollagen (with intact triple helix structure) to be used for prototyping new medical materials (e.g. synthetic tissues) will be gained from high-cell-density processes with a yeast expression system. Moreover, the experimental data collected will provide first estimates of manufacturing costs in terms of (i) raw materials and (ii) capability figures for the cultivation, downstream and further biosynthetic processing needed to achieve the mature functional form required.